{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:17:26Z","timestamp":1778887046234,"version":"3.51.4"},"publisher-location":"Cham","reference-count":188,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031972416","type":"print"},{"value":"9783031972423","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-97242-3_7","type":"book-chapter","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T20:23:40Z","timestamp":1755894220000},"page":"119-156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy in Head and Neck Cancer"],"prefix":"10.1007","author":[{"given":"Bridget E.","family":"Crossman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regan L.","family":"Harmon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Iida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candie Y.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan P.","family":"Pisick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany","family":"Glazer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall","family":"Kimple","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justine Yang","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deric","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"issue":"2","key":"7_CR1","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/medsci11020042","volume":"11","author":"A Barsouk","year":"2023","unstructured":"Barsouk A, Aluru JS, Rawla P, Saginala K, Barsouk A. Epidemiology, risk factors, and prevention of head and neck squamous cell carcinoma. Med Sci (Basel). 2023;11(2):42. https:\/\/doi.org\/10.3390\/medsci11020042.","journal-title":"Med Sci (Basel)"},{"issue":"3","key":"7_CR2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3390\/cancers17030548","volume":"17","author":"M Wierzbicka","year":"2025","unstructured":"Wierzbicka M, Pietruszewska W, Maciejczyk A, Markowski J. Trends in incidence and mortality of head and neck cancer subsites among elderly patients: a population-based analysis. Cancers (Basel). 2025;17(3):548. https:\/\/doi.org\/10.3390\/cancers17030548.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"7_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4161\/cbt.9.1.10905","volume":"9","author":"JD Klein","year":"2010","unstructured":"Klein JD, Grandis JR. The molecular pathogenesis of head and neck cancer. Cancer Biol Ther. 2010;9(1):1\u20137. https:\/\/doi.org\/10.4161\/cbt.9.1.10905.","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"7_CR4","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1158\/1055-9965.EPI-20-1702","volume":"30","author":"ET Chang","year":"2021","unstructured":"Chang ET, Ye W, Zeng YX, Adami HO. The evolving epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2021;30(6):1035\u201347. https:\/\/doi.org\/10.1158\/1055-9965.EPI-20-1702.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10","key":"7_CR5","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1158\/1055-9965.EPI-19-0038","volume":"28","author":"BA Mahal","year":"2019","unstructured":"Mahal BA, Catalano PJ, Haddad RI, Hanna GJ, Kass JI, Schoenfeld JD, et al. Incidence and demographic burden of HPV-associated oropharyngeal head and neck cancers in the united states. Cancer Epidemiol Biomarkers Prev. 2019;28(10):1660\u20137. https:\/\/doi.org\/10.1158\/1055-9965.EPI-19-0038.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"7_CR6","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.3390\/cancers12061543","volume":"12","author":"F Yan","year":"2020","unstructured":"Yan F, Knochelmann HM, Morgan PF, Kaczmar JM, Neskey DM, Graboyes EM, et al. The evolution of care of cancers of the head and neck region: state of the science in 2020. Cancers (Basel). 2020;12(6):1543. https:\/\/doi.org\/10.3390\/cancers12061543.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"7_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(23)00013-X","volume":"24","author":"H Mehanna","year":"2023","unstructured":"Mehanna H, Taberna M, von Buchwald C, Tous S, Brooks J, Mena M, et al. Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis. Lancet Oncol. 2023;24(3):239\u201351. https:\/\/doi.org\/10.1016\/S1470-2045(23)00013-X.","journal-title":"Lancet Oncol"},{"issue":"27","key":"7_CR8","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1200\/Jco.2010.29.2904","volume":"28","author":"D Rischin","year":"2010","unstructured":"Rischin D, Young RJ, Fisher R, Fox SB, Le QT, Peters LJ, et al. Prognostic significance of p16 and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol. 2010;28(27):4142\u20138. https:\/\/doi.org\/10.1200\/Jco.2010.29.2904.","journal-title":"J Clin Oncol"},{"key":"7_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1758-3284-2-15","volume":"2","author":"F Dayyani","year":"2010","unstructured":"Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2010;2:15. https:\/\/doi.org\/10.1186\/1758-3284-2-15.","journal-title":"Head Neck Oncol"},{"issue":"5","key":"7_CR10","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/JOM.0000000000001563","volume":"61","author":"P Khetan","year":"2019","unstructured":"Khetan P, Boffetta P, Luce D, Stucker I, Curado MP, Menezes A, et al. Occupations and the risk of head and neck cancer: a pooled analysis of the international head and neck cancer epidemiology (INHANCE) consortium. J Occup Environ Med. 2019;61(5):397\u2013404. https:\/\/doi.org\/10.1097\/JOM.0000000000001563.","journal-title":"J Occup Environ Med"},{"key":"7_CR11","doi-asserted-by":"publisher","unstructured":"Anderson G, Ebadi M, Vo K, Novak J, Govindarajan A, Amini A. An updated review on head and neck cancer treatment with radiation therapy. Cancers (Basel). 2021;13(19) https:\/\/doi.org\/10.3390\/cancers13194912.","DOI":"10.3390\/cancers13194912"},{"issue":"1","key":"7_CR12","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13014-023-02342-0","volume":"18","author":"S Zhang","year":"2023","unstructured":"Zhang S, Zeng N, Yang J, He J, Zhu F, Liao W, et al. Advancements of radiotherapy for recurrent head and neck cancer in modern era. Radiat Oncol. 2023;18(1):166. https:\/\/doi.org\/10.1186\/s13014-023-02342-0.","journal-title":"Radiat Oncol"},{"issue":"1","key":"7_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1056\/NEJMra1715715","volume":"382","author":"LQM Chow","year":"2020","unstructured":"Chow LQM. Head and neck cancer. N Engl J Med. 2020;382(1):60\u201372. https:\/\/doi.org\/10.1056\/NEJMra1715715.","journal-title":"N Engl J Med"},{"issue":"1","key":"7_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41392-022-01297-0","volume":"8","author":"Q Li","year":"2023","unstructured":"Li Q, Tie Y, Alu A, Ma X, Shi H. Targeted therapy for head and neck cancer: signaling pathways and clinical studies. Signal Transduct Target Ther. 2023;8(1):31. https:\/\/doi.org\/10.1038\/s41392-022-01297-0.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"7_CR15","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1186\/s12967-022-03774-0","volume":"20","author":"Y Li","year":"2022","unstructured":"Li Y, Jiang Y, Qiu B, Sun H, Wang J. Current radiotherapy for recurrent head and neck cancer in the modern era: a state-of-the-art review. J Transl Med. 2022;20(1):566. https:\/\/doi.org\/10.1186\/s12967-022-03774-0.","journal-title":"J Transl Med"},{"issue":"6","key":"7_CR16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa053422","volume":"354","author":"JA Bonner","year":"2006","unstructured":"Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New Engl J Med. 2006;354(6):567\u201378. https:\/\/doi.org\/10.1056\/NEJMoa053422.","journal-title":"New Engl J Med"},{"issue":"5","key":"7_CR17","first-page":"511","volume":"1","author":"JD Sato","year":"1983","unstructured":"Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med. 1983;1(5):511\u201329.","journal-title":"Mol Biol Med"},{"issue":"5","key":"7_CR18","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1073\/pnas.80.5.1337","volume":"80","author":"T Kawamoto","year":"1983","unstructured":"Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J. Growth-Stimulation of A431 cells by epidermal growth-factor\u2014identification of high-affinity receptors for epidermal growth-factor by an anti-receptor monoclonal-antibody. Proc Nat Acad Sci Biol. 1983;80(5):1337\u201341. https:\/\/doi.org\/10.1073\/pnas.80.5.1337.","journal-title":"Proc Nat Acad Sci Biol"},{"issue":"11","key":"7_CR19","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116\u201327. https:\/\/doi.org\/10.1056\/NEJMoa0802656.","journal-title":"N Engl J Med"},{"issue":"11","key":"7_CR20","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/s41416-019-0601-8","volume":"121","author":"TH Beckham","year":"2019","unstructured":"Beckham TH, Leeman JE, Xie P, Li X, Goldman DA, Zhang Z, et al. Long-term survival in patients with metastatic head and neck squamous cell carcinoma treated with metastasis-directed therapy. Br J Cancer. 2019;121(11):897\u2013903. https:\/\/doi.org\/10.1038\/s41416-019-0601-8.","journal-title":"Br J Cancer"},{"key":"7_CR21","doi-asserted-by":"publisher","unstructured":"Elmusrati A, Wang J, Wang CY. Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma. Int J Oral Sci. 2021;13(1) https:\/\/doi.org\/10.1038\/s41368-021-00131-7.","DOI":"10.1038\/s41368-021-00131-7"},{"key":"7_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.canlet.2021.03.009","volume":"507","author":"G Wang","year":"2021","unstructured":"Wang G, Zhang M, Cheng M, Wang X, Li K, Chen J, et al. Tumor microenvironment in head and neck squamous cell carcinoma: functions and regulatory mechanisms. Cancer Lett. 2021;507:55\u201369. https:\/\/doi.org\/10.1016\/j.canlet.2021.03.009.","journal-title":"Cancer Lett"},{"key":"7_CR23","doi-asserted-by":"publisher","first-page":"1021609","DOI":"10.3389\/fonc.2022.1021609","volume":"12","author":"MPS Damasio","year":"2022","unstructured":"Damasio MPS, Nascimento CS, Andrade LM, de Oliveira VL, Calzavara-Silva CE. The role of T-cells in head and neck squamous cell carcinoma: from immunity to immunotherapy. Front Oncol. 2022;12:1021609. https:\/\/doi.org\/10.3389\/fonc.2022.1021609.","journal-title":"Front Oncol"},{"issue":"2","key":"7_CR24","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov H, Orhan A, Christensen JP, G\u00f6genur I. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Br J Cancer. 2021;124(2):359\u201367. https:\/\/doi.org\/10.1038\/s41416-020-01048-4.","journal-title":"Br J Cancer"},{"key":"7_CR25","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3389\/fonc.2019.01084","volume":"9","author":"H-C Wang","year":"2019","unstructured":"Wang H-C, Chan L-P, Cho S-F. Targeting the immune microenvironment in the treatment of head and neck squamous cell carcinoma. Front Oncol. 2019;9:1084.","journal-title":"Front Oncol"},{"key":"7_CR26","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1146\/annurev-immunol-030409-101212","volume":"28","author":"J Zhu","year":"2010","unstructured":"Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol. 2010;28:445\u201389. https:\/\/doi.org\/10.1146\/annurev-immunol-030409-101212.","journal-title":"Annu Rev Immunol"},{"issue":"7","key":"7_CR27","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/icb.2010.37","volume":"88","author":"EM Janssen","year":"2010","unstructured":"Janssen EM, Lemmens EE, Gour N, Reboulet RA, Green DR, Schoenberger SP, et al. Distinct roles of cytolytic effector molecules for antigen-restricted killing by CTL in vivo. Immunol Cell Biol. 2010;88(7):761\u20135.","journal-title":"Immunol Cell Biol"},{"issue":"1","key":"7_CR28","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/0008-5472.CAN-05-1362","volume":"66","author":"S Olver","year":"2006","unstructured":"Olver S, Groves P, Buttigieg K, Morris ES, Janas ML, Kelso A, et al. Tumor-derived interleukin-4 reduces tumor clearance and deviates the cytokine and granzyme profile of tumor-induced CD8+ T cells. Cancer Res. 2006;66(1):571\u201380.","journal-title":"Cancer Res"},{"issue":"5","key":"7_CR29","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.otohns.2004.03.016","volume":"131","author":"A Sparano","year":"2004","unstructured":"Sparano A, Lathers DMR, Achille N, Petruzzelli GJ, Young MRI. Modulation of Th1 and Th2 cytokine profiles and their association with advanced head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 2004;131(5):573\u20136. https:\/\/doi.org\/10.1016\/j.otohns.2004.03.016.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"6","key":"7_CR30","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.17305\/bb.2024.10783","volume":"24","author":"R Wang","year":"2024","unstructured":"Wang R, Yin G, Guo W, Li N, Zhang Y, Chen X, et al. Analysis of Th1\/Th2 cytokine profile and clinical characteristics of patients with head and neck squamous cell carcinoma. Biomol Biomed. 2024;24(6):1776\u201384. https:\/\/doi.org\/10.17305\/bb.2024.10783.","journal-title":"Biomol Biomed"},{"key":"7_CR31","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3389\/fimmu.2014.00276","volume":"5","author":"SR Bailey","year":"2014","unstructured":"Bailey SR, Nelson MH, Himes RA, Li Z, Mehrotra S, Paulos CM. Th17 cells in cancer: the ultimate identity crisis. Front Immunol. 2014;5:276. https:\/\/doi.org\/10.3389\/fimmu.2014.00276.","journal-title":"Front Immunol"},{"issue":"8","key":"7_CR32","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/sj.bjc.6605891","volume":"103","author":"R Kesselring","year":"2010","unstructured":"Kesselring R, Thiel A, Pries R, Trenkle T, Wollenberg B. Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development. Br J Cancer. 2010;103(8):1245\u201354. https:\/\/doi.org\/10.1038\/sj.bjc.6605891.","journal-title":"Br J Cancer"},{"issue":"15","key":"7_CR33","doi-asserted-by":"publisher","first-page":"4345","DOI":"10.1158\/1078-0432.CCR-07-0472","volume":"13","author":"L Strauss","year":"2007","unstructured":"Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL. A unique subset of CD4+ CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-\u03b21 mediates suppression in the tumor microenvironment. Clin Cancer Res. 2007;13(15):4345\u201354.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"7_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1158\/1078-0432.CCR-14-1711","volume":"21","author":"DT Weed","year":"2015","unstructured":"Weed DT, Vella JL, Reis IM, De la Fuente AC, Gomez C, Sargi Z, et al. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. Clin Cancer Res. 2015;21(1):39\u201348.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"7_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071908","volume":"8","author":"DT Weed","year":"2013","unstructured":"Weed DT, Walker G, De La Fuente AC, Nazarian R, Vella JL, Gomez-Fernandez CR, et al. FOXP3 subcellular localization predicts recurrence in oral squamous cell carcinoma. PLoS One. 2013;8(8):e71908.","journal-title":"PLoS One"},{"issue":"1","key":"7_CR36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","volume":"41","author":"PJ Murray","year":"2014","unstructured":"Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14\u201320.","journal-title":"Immunity"},{"issue":"4","key":"7_CR37","first-page":"338","volume":"6","author":"E Weagel","year":"2015","unstructured":"Weagel E, Smith C, Liu P, Robison R, O\u2019neill K. Macrophage polarization and its role in cancer. J Clin Cell Immunol. 2015;6(4):338.","journal-title":"J Clin Cell Immunol"},{"issue":"3","key":"7_CR38","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1172\/JCI59643","volume":"122","author":"A Sica","year":"2012","unstructured":"Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122(3):787\u201395.","journal-title":"J Clin Invest"},{"issue":"3","key":"7_CR39","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.oraloncology.2012.09.012","volume":"49","author":"NL Costa","year":"2013","unstructured":"Costa NL, Valadares MC, Souza PPC, Mendon\u00e7a EF, Oliveira JC, Silva TA, et al. Tumor-associated macrophages and the profile of inflammatory cytokines in oral squamous cell carcinoma. Oral Oncol. 2013;49(3):216\u201323.","journal-title":"Oral Oncol"},{"issue":"1","key":"7_CR40","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.oraloncology.2014.09.006","volume":"51","author":"GT Wolf","year":"2015","unstructured":"Wolf GT, Chepeha DB, Bellile E, Nguyen A, Thomas D, McHugh J. Tumor infiltrating lymphocytes (TIL) and prognosis in oral cavity squamous carcinoma: a preliminary study. Oral Oncol. 2015;51(1):90\u20135.","journal-title":"Oral Oncol"},{"key":"7_CR41","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00430-010-0151-4","volume":"199","author":"E Ribechini","year":"2010","unstructured":"Ribechini E, Greifenberg V, Sandwick S, Lutz MB. Subsets, expansion and activation of myeloid-derived suppressor cells. Med Microbiol Immunol. 2010;199:273\u201381.","journal-title":"Med Microbiol Immunol"},{"issue":"4","key":"7_CR42","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1158\/0008-5472.CAN-11-1792","volume":"72","author":"AM Lesokhin","year":"2012","unstructured":"Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, et al. Monocytic CCR2+ myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res. 2012;72(4):876\u201386.","journal-title":"Cancer Res"},{"issue":"9","key":"7_CR43","doi-asserted-by":"publisher","first-page":"5693","DOI":"10.4049\/jimmunol.0900092","volume":"182","author":"CA Corzo","year":"2009","unstructured":"Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol. 2009;182(9):5693\u2013701.","journal-title":"J Immunol"},{"issue":"2","key":"7_CR44","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","volume":"19","author":"F Veglia","year":"2018","unstructured":"Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018;19(2):108\u201319.","journal-title":"Nat Immunol"},{"issue":"1","key":"7_CR45","doi-asserted-by":"publisher","first-page":"240","DOI":"10.4049\/jimmunol.182.1.240","volume":"182","author":"H Li","year":"2009","unstructured":"Li H, Han Y, Guo Q, Zhang M, Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-\u03b21. J Immunol. 2009;182(1):240\u20139.","journal-title":"J Immunol"},{"issue":"19","key":"7_CR46","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1158\/1078-0432.CCR-17-3726","volume":"24","author":"S Lang","year":"2018","unstructured":"Lang S, Bruderek K, Kaspar C, H\u00f6ing B, Kanaan O, Dominas N, et al. Clinical relevance and suppressive capacity of human myeloid-derived suppressor cell subsets. Clin Cancer Res. 2018;24(19):4834\u201344.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"7_CR47","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/hed.24595","volume":"39","author":"W-C Chen","year":"2017","unstructured":"Chen W-C, Lai C-H, Chuang H-C, Lin P-Y, Chen M-F. Inflammation-induced myeloid-derived suppressor cells associated with squamous cell carcinoma of the head and neck. Head Neck. 2017;39(2):347\u201355. https:\/\/doi.org\/10.1002\/hed.24595.","journal-title":"Head Neck"},{"issue":"11","key":"7_CR48","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","volume":"22","author":"MA Cooper","year":"2001","unstructured":"Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22(11):633\u201340.","journal-title":"Trends Immunol"},{"issue":"22","key":"7_CR49","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1158\/1078-0432.CCR-15-0685","volume":"21","author":"L Mart\u00ednez-Lostao","year":"2015","unstructured":"Mart\u00ednez-Lostao L, Anel A, Pardo J. How do cytotoxic lymphocytes kill cancer cells? Clin Cancer Res. 2015;21(22):5047\u201356.","journal-title":"Clin Cancer Res"},{"key":"7_CR50","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.coi.2018.02.004","volume":"51","author":"P Dhar","year":"2018","unstructured":"Dhar P, Wu JD. NKG2D and its ligands in cancer. Curr Opin Immunol. 2018;51:55\u201361. https:\/\/doi.org\/10.1016\/j.coi.2018.02.004.","journal-title":"Curr Opin Immunol"},{"key":"7_CR51","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3389\/fimmu.2017.00387","volume":"8","author":"S Weil","year":"2017","unstructured":"Weil S, Memmer S, Lechner A, Huppert V, Giannattasio A, Becker T, et al. Natural killer group 2D ligand depletion reconstitutes natural killer cell immunosurveillance of head and neck squamous cell carcinoma. Front Immunol. 2017;8:387.","journal-title":"Front Immunol"},{"issue":"3","key":"7_CR52","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","volume":"16","author":"JS O\u2019Donnell","year":"2019","unstructured":"O\u2019Donnell JS, Teng MWL, Smyth MJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol. 2019;16(3):151\u201367. https:\/\/doi.org\/10.1038\/s41571-018-0142-8.","journal-title":"Nat Rev Clin Oncol"},{"key":"7_CR53","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/978-3-030-91311-3_1","volume-title":"Interaction of immune and cancer cells","author":"JR Wilczynski","year":"2014","unstructured":"Wilczynski JR, Nowak M. Cancer immunoediting: elimination, equilibrium, and immune escape in solid tumors. In: Interaction of immune and cancer cells; 2014. p. 143\u2013205. https:\/\/doi.org\/10.1007\/978-3-030-91311-3_1."},{"issue":"2","key":"7_CR54","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3390\/cancers16020312","volume":"16","author":"KL Kostecki","year":"2024","unstructured":"Kostecki KL, Iida M, Crossman BE, Salgia R, Harari PM, Bruce JY, et al. Immune escape strategies in head and neck cancer: evade, resist, inhibit. Recruit Cancer. 2024;16(2):312.","journal-title":"Recruit Cancer"},{"issue":"1","key":"7_CR55","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/701657","volume":"2010","author":"A Duray","year":"2010","unstructured":"Duray A, Demoulin S, Hubert P, Delvenne P, Saussez S. Immune suppression in head and neck cancers: a review. J Immunol Res. 2010;2010(1):701657. https:\/\/doi.org\/10.1155\/2010\/701657.","journal-title":"J Immunol Res"},{"key":"7_CR56","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejca.2016.12.035","volume":"76","author":"JD Moy","year":"2017","unstructured":"Moy JD, Moskovitz JM, Ferris RL. Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. Eur J Cancer. 2017;76:152\u201366.","journal-title":"Eur J Cancer"},{"issue":"6","key":"7_CR57","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/s41388-023-02912-2","volume":"43","author":"X Luo","year":"2024","unstructured":"Luo X, Qiu Y, Fitzsimonds ZR, Wang Q, Chen Q, Lei YL. Immune escape of head and neck cancer mediated by the impaired MHC-I antigen presentation pathway. Oncogene. 2024;43(6):388\u201394. https:\/\/doi.org\/10.1038\/s41388-023-02912-2.","journal-title":"Oncogene"},{"issue":"7536","key":"7_CR58","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nature14129","volume":"517","author":"CGA Network","year":"2015","unstructured":"Network CGA. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576.","journal-title":"Nature"},{"issue":"7","key":"7_CR59","first-page":"2794","volume":"6","author":"JR Grandis","year":"2000","unstructured":"Grandis JR, Falkner DM, Melhem MF, Gooding WE, Drenning SD, Morel PA. Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences. Clin Cancer Res. 2000;6(7):2794\u2013802.","journal-title":"Clin Cancer Res"},{"key":"7_CR60","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1385\/IR:33:2:113","volume":"33","author":"RL Ferris","year":"2005","unstructured":"Ferris RL, Hunt JL, Ferrone S. Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res. 2005;33:113\u201333.","journal-title":"Immunol Res"},{"issue":"4","key":"7_CR61","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3892\/or_00000717","volume":"23","author":"N Bandoh","year":"2010","unstructured":"Bandoh N, Ogino T, Katayama A, Takahara M, Katada A, Hayashi T, et al. HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis. Oncol Rep. 2010;23(4):933\u20139.","journal-title":"Oncol Rep"},{"issue":"13","key":"7_CR62","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1158\/1078-0432.CCR-05-2750","volume":"12","author":"RL Ferris","year":"2006","unstructured":"Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res. 2006;12(13):3890\u20135.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"7_CR63","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41577-022-00707-2","volume":"22","author":"N Pishesha","year":"2022","unstructured":"Pishesha N, Harmand TJ, Ploegh HL. A guide to antigen processing and presentation. Nat Rev Immunol. 2022;22(12):751\u201364.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"7_CR64","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s00262-024-03789-0","volume":"73","author":"S Yan","year":"2024","unstructured":"Yan S, Zhang X, Lin Q, Du M, Li Y, He S, et al. Deciphering the interplay of HPV infection, MHC-II expression, and CXCL13+ CD4+ T cell activation in oropharyngeal cancer: implications for immunotherapy. Cancer Immunol Immunother. 2024;73(10):206.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"7_CR65","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s13046-022-02481-4","volume":"41","author":"A Tosi","year":"2022","unstructured":"Tosi A, Parisatto B, Menegaldo A, Spinato G, Guido M, Del Mistro A, et al. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-na\u00efve tumors with immune checkpoint inhibitors. J Exp Clin Cancer Res. 2022;41(1):279. https:\/\/doi.org\/10.1186\/s13046-022-02481-4.","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"7_CR66","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1158\/0008-5472.CAN-15-2001","volume":"76","author":"F Concha-Benavente","year":"2016","unstructured":"Concha-Benavente F, Srivastava RM, Trivedi S, Lei Y, Chandran U, Seethala RR, et al. Identification of the cell-intrinsic and-extrinsic pathways downstream of EGFR and IFN\u03b3 that induce PD-L1 expression in head and neck cancer. Cancer Res. 2016;76(5):1031\u201343.","journal-title":"Cancer Res"},{"issue":"11","key":"7_CR67","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887\u201395.","journal-title":"EMBO J"},{"issue":"16","key":"7_CR68","doi-asserted-by":"publisher","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-16-2819","volume":"23","author":"S Ludwig","year":"2017","unstructured":"Ludwig S, Floros T, Theodoraki M-N, Hong C-S, Jackson EK, Lang S, et al. Suppression of lymphocyte functions by plasma exosomes correlates with disease activity in patients with head and neck cancer. Clin Cancer Res. 2017;23(16):4843\u201354.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"7_CR69","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1158\/1078-0432.CCR-16-2586","volume":"23","author":"HD Skinner","year":"2017","unstructured":"Skinner HD, Giri U, Yang LP, Kumar M, Liu Y, Story MD, et al. Integrative analysis identifies a novel AXL\u2013PI3 Kinase\u2013PD-L1 signaling axis associated with radiation resistance in head and neck cancer. Clin Cancer Res. 2017;23(11):2713\u201322.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"7_CR70","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85330","volume":"2","author":"Y Latchman","year":"2001","unstructured":"Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261\u20138.","journal-title":"Nat Immunol"},{"issue":"12","key":"7_CR71","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1158\/1078-0432.CCR-16-1761","volume":"23","author":"JH Yearley","year":"2017","unstructured":"Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res. 2017;23(12):3158\u201367.","journal-title":"Clin Cancer Res"},{"key":"7_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-019-1310-0","volume":"38","author":"J Wu","year":"2019","unstructured":"Wu J, Gao F-x, Wang C, Qin M, Han F, Xu T, et al. IL-6 and IL-8 secreted by tumour cells impair the function of NK cells via the STAT3 pathway in oesophageal squamous cell carcinoma. J Exp Clin Cancer Res. 2019;38:1\u201315.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"7_CR73","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1002\/jcp.29108","volume":"235","author":"Y Chen","year":"2020","unstructured":"Chen Y, Di C, Zhang X, Wang J, Wang F, Yan JF, et al. Transforming growth factor \u03b2 signaling pathway: a promising therapeutic target for cancer. J Cell Physiol. 2020;235(3):1903\u201314.","journal-title":"J Cell Physiol"},{"issue":"2","key":"7_CR74","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.coi.2008.04.003","volume":"20","author":"NM Moutsopoulos","year":"2008","unstructured":"Moutsopoulos NM, Wen J, Wahl SM. TGF-\u03b2 and tumors\u2014an ill-fated alliance. Curr Opin Immunol. 2008;20(2):234\u201340.","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"7_CR75","first-page":"1812","volume":"7","author":"J Wolf","year":"2001","unstructured":"Wolf J, Chen Z, Dong G, Sunwoo J, Bancroft C, Capo D, et al. 1alpha promotes nuclear factor-kappaB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res. 2001;7(6):1812\u201320.","journal-title":"Clin Cancer Res"},{"issue":"14","key":"7_CR76","first-page":"3142","volume":"58","author":"KV Woods","year":"1998","unstructured":"Woods KV, Adler-Storthz K, Clayman GL, Francis GM, Grimm EA. Interleukin-1 regulates interleukin-6 secretion in human oral squamous cell carcinoma in vitro: possible influence of p53 but not human papillomavirus E6\/E7. Cancer Res. 1998;58(14):3142\u20139.","journal-title":"Cancer Res"},{"key":"7_CR77","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3389\/fimmu.2013.00192","volume":"4","author":"KM Hargadon","year":"2013","unstructured":"Hargadon KM. Tumor-altered dendritic cell function: implications for anti-tumor immunity. Front Immunol. 2013;4:192.","journal-title":"Front Immunol"},{"issue":"6","key":"7_CR78","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.4049\/jimmunol.173.6.3844","volume":"173","author":"S-J Park","year":"2004","unstructured":"Park S-J, Nakagawa T, Kitamura H, Atsumi T, Kamon H, Sawa S-i, et al. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol. 2004;173(6):3844\u201354.","journal-title":"J Immunol"},{"issue":"1","key":"7_CR79","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bbcan.2009.02.004","volume":"1796","author":"SB Coffelt","year":"2009","unstructured":"Coffelt SB, Hughes R, Lewis CE. Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta Rev Cancer. 2009;1796(1):11\u20138.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"6","key":"7_CR80","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/ijc.1407","volume":"93","author":"C Liss","year":"2001","unstructured":"Liss C, Fekete MJ, Hasina R, Lam CD, Lingen MW. Paracrine angiogenic loop between head-and-neck squamous-cell carcinomas and macrophages. Int J Cancer. 2001;93(6):781\u20135.","journal-title":"Int J Cancer"},{"issue":"12","key":"7_CR81","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.it.2004.09.015","volume":"25","author":"A Mantovani","year":"2004","unstructured":"Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25(12):677\u201386.","journal-title":"Trends Immunol"},{"issue":"1","key":"7_CR82","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1158\/0008-5472.CAN-15-0869","volume":"76","author":"E Van Overmeire","year":"2016","unstructured":"Van Overmeire E, Stijlemans B, Heymann F, Keirsse J, Morias Y, Elkrim Y, et al. M-CSF and GM-CSF receptor signaling differentially regulate monocyte maturation and macrophage polarization in the tumor microenvironment. Cancer Res. 2016;76(1):35\u201342.","journal-title":"Cancer Res"},{"issue":"7355","key":"7_CR83","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature10169","volume":"475","author":"A Facciabene","year":"2011","unstructured":"Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang L-P, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature. 2011;475(7355):226\u201330.","journal-title":"Nature"},{"key":"7_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2013.12.005","volume":"27","author":"H Nishikawa","year":"2014","unstructured":"Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol. 2014;27:1\u20137.","journal-title":"Curr Opin Immunol"},{"issue":"22","key":"7_CR85","doi-asserted-by":"publisher","first-page":"8451","DOI":"10.1158\/0008-5472.CAN-04-1987","volume":"64","author":"L Zou","year":"2004","unstructured":"Zou L, Barnett B, Safah H, LaRussa VF, Evdemon-Hogan M, Mottram P, et al. Bone marrow is a reservoir for CD4+ CD25+ regulatory T cells that traffic through CXCL12\/CXCR4 signals. Cancer Res. 2004;64(22):8451\u20135.","journal-title":"Cancer Res"},{"issue":"8","key":"7_CR86","doi-asserted-by":"publisher","first-page":"4488","DOI":"10.1158\/0008-5472.CAN-05-4217","volume":"66","author":"B Valzasina","year":"2006","unstructured":"Valzasina B, Piconese S, Guiducci C, Colombo MP. Tumor-induced expansion of regulatory T cells by conversion of CD4+ CD25\u2212 lymphocytes is thymus and proliferation independent. Cancer Res. 2006;66(8):4488\u201395.","journal-title":"Cancer Res"},{"key":"7_CR87","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00262-003-0433-4","volume":"53","author":"GR Thomas","year":"2004","unstructured":"Thomas GR, Chen Z, Leukinova E, Van Waes C, Wen J. Cytokines IL-1\u03b1, IL-6, and GM-CSF constitutively secreted by oral squamous carcinoma induce down-regulation of CD80 costimulatory molecule expression: restoration by interferon \u03b3. Cancer Immunol Immunother. 2004;53:33\u201340.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"7_CR88","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.cyto.2003.11.005","volume":"25","author":"DM Lathers","year":"2004","unstructured":"Lathers DM, Young MRI. Increased aberrance of cytokine expression in plasma of patients with more advanced squamous cell carcinoma of the head and neck. Cytokine. 2004;25(5):220\u20138.","journal-title":"Cytokine"},{"key":"7_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:1\u201314.","journal-title":"Genome Med"},{"issue":"1","key":"7_CR90","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1146\/annurev-immunol-042617-053402","volume":"37","author":"TN Schumacher","year":"2019","unstructured":"Schumacher TN, Scheper W, Kvistborg P. Cancer neoantigens. Annu Rev Immunol. 2019;37(1):173\u2013200.","journal-title":"Annu Rev Immunol"},{"issue":"6230","key":"7_CR91","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69\u201374.","journal-title":"Science"},{"issue":"1","key":"7_CR92","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12967-024-04937-x","volume":"22","author":"JP Rodrigo","year":"2024","unstructured":"Rodrigo JP, S\u00e1nchez-Canteli M, Otero-Rosales M, Mart\u00ednez-Camblor P, Hermida-Prado F, Garc\u00eda-Pedrero JM. Tumor mutational burden predictability in head and neck squamous cell carcinoma patients treated with immunotherapy: systematic review and meta-analysis. J Transl Med. 2024;22(1):135. https:\/\/doi.org\/10.1186\/s12967-024-04937-x.","journal-title":"J Transl Med"},{"issue":"1","key":"7_CR93","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1634\/theoncologist.2019-0244","volume":"25","author":"SJ Klempner","year":"2020","unstructured":"Klempner SJ, Fabrizio D, Bane S, Reinhart M, Peoples T, Ali SM, et al. Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence. Oncologist. 2020;25(1):e147\u2013e59. https:\/\/doi.org\/10.1634\/theoncologist.2019-0244.","journal-title":"Oncologist"},{"key":"7_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.751407","volume":"12","author":"Y Li","year":"2021","unstructured":"Li Y, Ma Y, Wu Z, Zeng F, Song B, Zhang Y, et al. Tumor mutational burden predicting the efficacy of immune checkpoint inhibitors in colorectal cancer: a systematic review and meta-analysis. Front Immunol. 2021;12:751407.","journal-title":"Front Immunol"},{"issue":"9","key":"7_CR95","first-page":"e1629258","volume":"8","author":"D Cao","year":"2019","unstructured":"Cao D, Xu H, Xu X, Guo T, Ge W. High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients. Onco Targets Ther. 2019;8(9):e1629258.","journal-title":"Onco Targets Ther"},{"issue":"9","key":"7_CR96","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","volume":"24","author":"DR Gandara","year":"2018","unstructured":"Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24(9):1441\u20138.","journal-title":"Nat Med"},{"issue":"2","key":"7_CR97","doi-asserted-by":"publisher","DOI":"10.1002\/wsbm.1539","volume":"14","author":"SF Gameiro","year":"2022","unstructured":"Gameiro SF, Evans AM, Mymryk JS. The tumor immune microenvironments of HPV+ and HPV\u2212 head and neck cancers. WIREs Mech Dis. 2022;14(2):e1539.","journal-title":"WIREs Mech Dis"},{"key":"7_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2022.105774","volume":"127","author":"HA Qureshi","year":"2022","unstructured":"Qureshi HA, Zhu X, Yang GH, Steadele M, Pierce RH, Futran ND, et al. Impact of HPV status on immune responses in head and neck squamous cell carcinoma. Oral Oncol. 2022;127:105774.","journal-title":"Oral Oncol"},{"issue":"1","key":"7_CR99","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L. Neoantigens: promising targets for cancer therapy. Signal Transduct Target Ther. 2023;8(1):9. https:\/\/doi.org\/10.1038\/s41392-022-01270-x.","journal-title":"Signal Transduct Target Ther"},{"key":"7_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.731798","volume":"12","author":"J Liu","year":"2021","unstructured":"Liu J, Chen Z, Li Y, Zhao W, Wu J, Zhang Z. PD-1\/PD-l1 checkpoint inhibitors in tumor immunotherapy. Front Pharmacol. 2021;12:731798. https:\/\/doi.org\/10.3389\/fphar.2021.731798.","journal-title":"Front Pharmacol"},{"key":"7_CR101","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1146\/annurev.immunol.021908.132706","volume":"27","author":"JE Smith-Garvin","year":"2009","unstructured":"Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol. 2009;27:591\u2013619. https:\/\/doi.org\/10.1146\/annurev.immunol.021908.132706.","journal-title":"Annu Rev Immunol"},{"issue":"7","key":"7_CR102","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027\u201334. https:\/\/doi.org\/10.1084\/jem.192.7.1027.","journal-title":"J Exp Med"},{"issue":"10","key":"7_CR103","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/emmm.201100165","volume":"3","author":"K Karwacz","year":"2011","unstructured":"Karwacz K, Bricogne C, MacDonald D, Arce F, Bennett CL, Collins M, et al. PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells. EMBO Mol Med. 2011;3(10):581\u201392. https:\/\/doi.org\/10.1002\/emmm.201100165.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"7_CR104","first-page":"2011.5","volume":"1","author":"D Escors","year":"2011","unstructured":"Escors D, Bricogne C, Arce F, Kochan G, Karwacz K. On the mechanism of T cell receptor down-modulation and its physiological significance. J Biosci Med. 2011;1(1):2011.5.","journal-title":"J Biosci Med"},{"issue":"4","key":"7_CR105","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1084\/jem.20160801","volume":"214","author":"VR Juneja","year":"2017","unstructured":"Juneja VR, McGuire KA, Manguso RT, LaFleur MW, Collins N, Haining WN, et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017;214(4):895\u2013904. https:\/\/doi.org\/10.1084\/jem.20160801.","journal-title":"J Exp Med"},{"issue":"7","key":"7_CR106","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","volume":"17","author":"TY Seiwert","year":"2016","unstructured":"Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(16)30066-3.","journal-title":"Lancet Oncol"},{"issue":"7","key":"7_CR107","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1634\/theoncologist.2016-0496","volume":"22","author":"E Larkins","year":"2017","unstructured":"Larkins E, Blumenthal GM, Yuan W, He K, Sridhara R, Subramaniam S, et al. FDA approval summary: pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy. Oncologist. 2017;22(7):873\u20138. https:\/\/doi.org\/10.1634\/theoncologist.2016-0496.","journal-title":"Oncologist"},{"issue":"10212","key":"7_CR108","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro G Jr, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(19)32591-7.","journal-title":"Lancet"},{"issue":"19","key":"7_CR109","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856\u201367. https:\/\/doi.org\/10.1056\/NEJMoa1602252.","journal-title":"N Engl J Med"},{"issue":"7","key":"7_CR110","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1200\/JCO.20.02712","volume":"39","author":"FH Wang","year":"2021","unstructured":"Wang FH, Wei XL, Feng J, Li Q, Xu N, Hu XC, et al. Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02). J Clin Oncol. 2021;39(7):704\u201312. https:\/\/doi.org\/10.1200\/JCO.20.02712.","journal-title":"J Clin Oncol"},{"issue":"20","key":"7_CR111","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1001\/jama.2023.20181","volume":"330","author":"HQ Mai","year":"2023","unstructured":"Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, et al. Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial. JAMA. 2023;330(20):1961\u201370. https:\/\/doi.org\/10.1001\/jama.2023.20181.","journal-title":"JAMA"},{"key":"7_CR112","doi-asserted-by":"publisher","first-page":"A481","DOI":"10.1136\/jitc-2020-SITC2020.0804","volume":"8","author":"XZ Chen","year":"2020","unstructured":"Chen XZ, Wang W, Zou QF, Li JG, Hu CS, Hu CS, et al. A phase II study of the anti-programmed cell death-1 (Pd-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (Npc) who had progressed after two or more lines of chemotherapy. J Immunother Cancer. 2020;8:A481\u2013A. https:\/\/doi.org\/10.1136\/jitc-2020-SITC2020.0804.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"7_CR113","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","volume":"39","author":"EI Buchbinder","year":"2016","unstructured":"Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):98\u2013106. https:\/\/doi.org\/10.1097\/COC.0000000000000239.","journal-title":"Am J Clin Oncol"},{"issue":"5899","key":"7_CR114","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1126\/science.1160062","volume":"322","author":"K Wing","year":"2008","unstructured":"Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322(5899):271\u20135. https:\/\/doi.org\/10.1126\/science.1160062.","journal-title":"Science"},{"issue":"6029","key":"7_CR115","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1126\/science.1202947","volume":"332","author":"OS Qureshi","year":"2011","unstructured":"Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011;332(6029):600\u20133. https:\/\/doi.org\/10.1126\/science.1202947.","journal-title":"Science"},{"key":"7_CR116","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","volume":"224","author":"BT Fife","year":"2008","unstructured":"Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008;224:166\u201382. https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00662.x.","journal-title":"Immunol Rev"},{"issue":"9","key":"7_CR117","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1158\/1078-0432.CCR-13-2648","volume":"20","author":"L Robert","year":"2014","unstructured":"Robert L, Tsoi J, Wang X, Emerson R, Homet B, Chodon T, et al. CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res. 2014;20(9):2424\u201332. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2648.","journal-title":"Clin Cancer Res"},{"key":"7_CR118","doi-asserted-by":"publisher","unstructured":"Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers (Basel). 2020;12(3) https:\/\/doi.org\/10.3390\/cancers12030738.","DOI":"10.3390\/cancers12030738"},{"issue":"12","key":"7_CR119","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1200\/JCO.22.00332","volume":"41","author":"RI Haddad","year":"2023","unstructured":"Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J, et al. Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent\/metastatic squamous cell carcinoma of the head and neck: the final results of checkmate 651. J Clin Oncol. 2023;41(12):2166\u201380. https:\/\/doi.org\/10.1200\/JCO.22.00332.","journal-title":"J Clin Oncol"},{"issue":"6","key":"7_CR120","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1001\/jamaoncol.2023.0147","volume":"9","author":"KJ Harrington","year":"2023","unstructured":"Harrington KJ, Ferris RL, Gillison M, Tahara M, Argiris A, Fayette J, et al. Efficacy and safety of nivolumab plus ipilimumab vs nivolumab alone for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck: the phase 2 checkmate 714 randomized clinical trial. JAMA Oncol. 2023;9(6):779\u201389. https:\/\/doi.org\/10.1001\/jamaoncol.2023.0147.","journal-title":"JAMA Oncol"},{"issue":"7","key":"7_CR121","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/j.annonc.2020.04.001","volume":"31","author":"RL Ferris","year":"2020","unstructured":"Ferris RL, Haddad R, Even C, Tahara M, Dvorkin M, Ciuleanu TE, et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann Oncol. 2020;31(7):942\u201350. https:\/\/doi.org\/10.1016\/j.annonc.2020.04.001.","journal-title":"Ann Oncol"},{"issue":"1","key":"7_CR122","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1186\/s12885-024-13074-z","volume":"24","author":"T Mandal","year":"2024","unstructured":"Mandal T, Gnanasegaran S, Rodrigues G, Kashipathi S, Tiwari A, Dubey AK, et al. Targeting LLT1 as a potential immunotherapy option for cancer patients non-responsive to existing checkpoint therapies in multiple solid tumors. BMC Cancer. 2024;24(1):1365. https:\/\/doi.org\/10.1186\/s12885-024-13074-z.","journal-title":"BMC Cancer"},{"key":"7_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113066","volume":"151","author":"S Guo","year":"2022","unstructured":"Guo S, Han F, Zhu W. CD39\u2014a bright target for cancer immunotherapy. Biomed Pharmacother. 2022;151:113066. https:\/\/doi.org\/10.1016\/j.biopha.2022.113066.","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"7_CR124","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1007\/s00262-021-02921-8","volume":"70","author":"K Hansen","year":"2021","unstructured":"Hansen K, Kumar S, Logronio K, Whelan S, Qurashi S, Cheng HY, et al. COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade. Cancer Immunol Immunother. 2021;70(12):3525\u201340. https:\/\/doi.org\/10.1007\/s00262-021-02921-8.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"7_CR125","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41368-020-0084-8","volume":"12","author":"Z Mei","year":"2020","unstructured":"Mei Z, Huang J, Qiao B, Lam AK. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma. Int J Oral Sci. 2020;12(1):16. https:\/\/doi.org\/10.1038\/s41368-020-0084-8.","journal-title":"Int J Oral Sci"},{"issue":"1","key":"7_CR126","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-020-00917-y","volume":"13","author":"X Huang","year":"2020","unstructured":"Huang X, Zhang X, Li E, Zhang G, Wang X, Tang T, et al. VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy. J Hematol Oncol. 2020;13(1):83. https:\/\/doi.org\/10.1186\/s13045-020-00917-y.","journal-title":"J Hematol Oncol"},{"issue":"5-6","key":"7_CR127","doi-asserted-by":"publisher","first-page":"176","DOI":"10.18632\/genesandcancer.180","volume":"9","author":"L Long","year":"2018","unstructured":"Long L, Zhang X, Chen F, Pan Q, Phiphatwatchara P, Zeng Y, et al. The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy. Genes Cancer. 2018;9(5-6):176\u201389. https:\/\/doi.org\/10.18632\/genesandcancer.180.","journal-title":"Genes Cancer"},{"issue":"3","key":"7_CR128","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/icb.2014.93","volume":"93","author":"AM Huehls","year":"2015","unstructured":"Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol. 2015;93(3):290\u20136. https:\/\/doi.org\/10.1038\/icb.2014.93.","journal-title":"Immunol Cell Biol"},{"key":"7_CR129","doi-asserted-by":"publisher","unstructured":"Psyrri A, Seiwert TY, Jimeno A. Molecular pathways in head and neck cancer: EGFR, PI3K, and more. Am Soc Clin Oncol Educ Book. 2013:246\u201355. https:\/\/doi.org\/10.14694\/EdBook_AM.2013.33.246.","DOI":"10.14694\/EdBook_AM.2013.33.246"},{"issue":"1","key":"7_CR130","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.semradonc.2008.09.009","volume":"19","author":"PM Harari","year":"2009","unstructured":"Harari PM, Wheeler DL, Grandis JR. Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond. Semin Radiat Oncol. 2009;19(1):63\u20138. https:\/\/doi.org\/10.1016\/j.semradonc.2008.09.009.","journal-title":"Semin Radiat Oncol"},{"issue":"9","key":"7_CR131","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/j.stem.2021.04.011","volume":"28","author":"C Wang","year":"2021","unstructured":"Wang C, Li Y, Jia L, Kim JK, Li J, Deng P, et al. CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance. Cell Stem Cell. 2021;28(9):1597\u2013613.e7. https:\/\/doi.org\/10.1016\/j.stem.2021.04.011.","journal-title":"Cell Stem Cell"},{"issue":"5","key":"7_CR132","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/PPO.0000000000000619","volume":"28","author":"SM Centuori","year":"2022","unstructured":"Centuori SM, Bauman JE. c-Met signaling as a therapeutic target in head and neck cancer. Cancer J. 2022;28(5):346\u201353. https:\/\/doi.org\/10.1097\/PPO.0000000000000619.","journal-title":"Cancer J"},{"issue":"3-4","key":"7_CR133","doi-asserted-by":"publisher","first-page":"84","DOI":"10.18632\/genesandcancer.40","volume":"6","author":"A Shvartsur","year":"2015","unstructured":"Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications. Genes Cancer. 2015;6(3-4):84\u2013105. https:\/\/doi.org\/10.18632\/genesandcancer.40.","journal-title":"Genes Cancer"},{"issue":"2","key":"7_CR134","doi-asserted-by":"publisher","first-page":"2256904","DOI":"10.1080\/21645515.2023.2256904","volume":"19","author":"T Huan","year":"2023","unstructured":"Huan T, Guan B, Li H, Tu X, Zhang C, Tang B. Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer. Hum Vaccin Immunother. 2023;19(2):2256904. https:\/\/doi.org\/10.1080\/21645515.2023.2256904.","journal-title":"Hum Vaccin Immunother"},{"key":"7_CR135","doi-asserted-by":"publisher","first-page":"1207276","DOI":"10.3389\/fimmu.2023.1207276","volume":"14","author":"M Zhang","year":"2023","unstructured":"Zhang M, Lam KP, Xu S. Natural Killer Cell Engagers (NKCEs): a new frontier in cancer immunotherapy. Front Immunol. 2023;14:1207276. https:\/\/doi.org\/10.3389\/fimmu.2023.1207276.","journal-title":"Front Immunol"},{"issue":"4","key":"7_CR136","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein C, Brinkmann U, Reichert JM, Kontermann RE. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov. 2024;23(4):301\u201319. https:\/\/doi.org\/10.1038\/s41573-024-00896-6.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"7_CR137","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","volume":"10","author":"M Herrera","year":"2024","unstructured":"Herrera M, Pretelli G, Desai J, Garralda E, Siu LL, Steiner TM, et al. Bispecific antibodies: advancing precision oncology. Trends Cancer. 2024;10(10):893\u2013919. https:\/\/doi.org\/10.1016\/j.trecan.2024.07.002.","journal-title":"Trends Cancer"},{"issue":"13","key":"7_CR138","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1158\/1538-7445.AM2021-1826","volume":"81","author":"KH Pyo","year":"2021","unstructured":"Pyo KH, Koh YJ, Synn CB, Kim JH, Byeon Y, Jo HN, et al. Comprehensive preclinical study on GI-101, a novel CD80-IgG4-IL2 variant protein, as a therapeutic antibody candidate with bispecific immuno-oncology target. Cancer Res. 2021;81(13):1826.","journal-title":"Cancer Res"},{"issue":"12","key":"7_CR139","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1158\/1538-7445.AM2022-3518","volume":"82","author":"KD Moynihan","year":"2022","unstructured":"Moynihan KD, Pappas D, Park T, Chen W, Ni I, Bessette P, et al. AB248 is a CD8+T cell selective IL-2 designed for superior safety and anti-tumor efficacy. Cancer Res. 2022;82(12):3518.","journal-title":"Cancer Res"},{"issue":"1","key":"7_CR140","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","volume":"120","author":"P Berraondo","year":"2019","unstructured":"Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Perez-Gracia JL, et al. Cytokines in clinical cancer immunotherapy. Br J Cancer. 2019;120(1):6\u201315. https:\/\/doi.org\/10.1038\/s41416-018-0328-y.","journal-title":"Br J Cancer"},{"issue":"12","key":"7_CR141","doi-asserted-by":"publisher","first-page":"a028472","DOI":"10.1101\/cshperspect.a028472","volume":"10","author":"TA Waldmann","year":"2018","unstructured":"Waldmann TA. Cytokines in cancer immunotherapy. Cold Spring Harb Perspect Biol. 2018;10(12):a028472. https:\/\/doi.org\/10.1101\/cshperspect.a028472.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"7_CR142","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.952231","volume":"13","author":"Z Jia","year":"2022","unstructured":"Jia Z, Ragoonanan D, Mahadeo KM, Gill J, Gorlick R, Shpal E, et al. IL12 immune therapy clinical trial review: novel strategies for avoiding CRS-associated cytokines. Front Immunol. 2022;13:952231. https:\/\/doi.org\/10.3389\/fimmu.2022.952231.","journal-title":"Front Immunol"},{"issue":"7","key":"7_CR143","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179431","volume":"12","author":"D Charych","year":"2017","unstructured":"Charych D, Khalili S, Dixit V, Kirk P, Chang T, Langowski J, et al. Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy. PLoS One. 2017;12(7):e0179431. https:\/\/doi.org\/10.1371\/journal.pone.0179431.","journal-title":"PLoS One"},{"issue":"3","key":"7_CR144","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1277306","volume":"6","author":"C Klein","year":"2017","unstructured":"Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Onco Targets Ther. 2017;6(3):e1277306. https:\/\/doi.org\/10.1080\/2162402X.2016.1277306.","journal-title":"Onco Targets Ther"},{"issue":"7395","key":"7_CR145","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nature10975","volume":"484","author":"AM Levin","year":"2012","unstructured":"Levin AM, Bates DL, Ring AM, Krieg C, Lin JT, Su L, et al. Exploiting a natural conformational switch to engineer an interleukin-2 \u2018superkine\u2019. Nature. 2012;484(7395):529\u201333. https:\/\/doi.org\/10.1038\/nature10975.","journal-title":"Nature"},{"key":"7_CR146","doi-asserted-by":"publisher","unstructured":"Izar B, Zamarin D, Spigel DR, Hoimes CJ, McDermott DF, Sehgal K, et al. Initial results from a phase 1a\/1b study of STK-012, a first-in-class \u03b1\/\u03b2 IL-2 receptor biased partial agonist in advanced solid tumors (NCT05098132). Cancer Res. 2024;84(7) https:\/\/doi.org\/10.1158\/1538-7445.Am2024-Ct183.","DOI":"10.1158\/1538-7445.Am2024-Ct183"},{"issue":"3","key":"7_CR147","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00109-001-0307-1","volume":"80","author":"F Biet","year":"2002","unstructured":"Biet F, Locht C, Kremer L. Immunoregulatory functions of interleukin 18 and its role in defense against bacterial pathogens. J Mol Med (Berl). 2002;80(3):147\u201362. https:\/\/doi.org\/10.1007\/s00109-001-0307-1.","journal-title":"J Mol Med (Berl)"},{"issue":"10","key":"7_CR148","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1038\/s41422-020-00396-3","volume":"30","author":"KO Dixon","year":"2020","unstructured":"Dixon KO, Kuchroo VK. IL-18: throwing off the shackles to boost anti-tumor immunity. Cell Res. 2020;30(10):831\u20132. https:\/\/doi.org\/10.1038\/s41422-020-00396-3.","journal-title":"Cell Res"},{"issue":"7","key":"7_CR149","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nri2343","volume":"8","author":"DA Vignali","year":"2008","unstructured":"Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8(7):523\u201332. https:\/\/doi.org\/10.1038\/nri2343.","journal-title":"Nat Rev Immunol"},{"key":"7_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108469","volume":"104","author":"BJ Chen","year":"2022","unstructured":"Chen BJ, Zhao JW, Zhang DH, Zheng AH, Wu GQ. Immunotherapy of cancer by targeting regulatory T cells. Int Immunopharmacol. 2022;104:108469. https:\/\/doi.org\/10.1016\/j.intimp.2021.108469.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"7_CR151","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.it.2025.01.001","volume":"46","author":"Y Wen","year":"2025","unstructured":"Wen Y, Xia Y, Yang X, Li H, Gao Q. CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells. Trends Immunol. 2025;46(2):153\u201365. https:\/\/doi.org\/10.1016\/j.it.2025.01.001.","journal-title":"Trends Immunol"},{"issue":"1","key":"7_CR152","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1186\/s12967-024-05518-8","volume":"22","author":"Q Chen","year":"2024","unstructured":"Chen Q, Shen M, Yan M, Han X, Mu S, Li Y, et al. Targeting tumor-infiltrating CCR8(+) regulatory T cells induces antitumor immunity through functional restoration of CD4(+) T(convs) and CD8(+) T cells in colorectal cancer. J Transl Med. 2024;22(1):709. https:\/\/doi.org\/10.1186\/s12967-024-05518-8.","journal-title":"J Transl Med"},{"key":"7_CR153","doi-asserted-by":"publisher","unstructured":"Devaraja K, Aggarwal S, Singh M. Therapeutic vaccination in head and neck squamous cell carcinoma\u2014a review. Vaccines (Basel). 2023;11(3) https:\/\/doi.org\/10.3390\/vaccines11030634.","DOI":"10.3390\/vaccines11030634"},{"issue":"4","key":"7_CR154","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41418-019-0297-6","volume":"26","author":"N Germic","year":"2019","unstructured":"Germic N, Frangez Z, Yousefi S, Simon HU. Regulation of the innate immune system by autophagy: monocytes, macrophages, dendritic cells and antigen presentation. Cell Death Differ. 2019;26(4):715\u201327. https:\/\/doi.org\/10.1038\/s41418-019-0297-6.","journal-title":"Cell Death Differ"},{"issue":"17","key":"7_CR155","doi-asserted-by":"publisher","first-page":"6889","DOI":"10.1158\/0008-5472.CAN-08-0161","volume":"68","author":"Y Li","year":"2008","unstructured":"Li Y, Wang LX, Yang G, Hao F, Urba WJ, Hu HM. Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res. 2008;68(17):6889\u201395. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-0161.","journal-title":"Cancer Res"},{"issue":"22","key":"7_CR156","doi-asserted-by":"publisher","first-page":"7047","DOI":"10.1158\/1078-0432.CCR-11-0951","volume":"17","author":"Y Li","year":"2011","unstructured":"Li Y, Wang LX, Pang P, Cui Z, Aung S, Haley D, et al. Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy. Clin Cancer Res. 2011;17(22):7047\u201357. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0951.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"7_CR157","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21(6):360\u201378. https:\/\/doi.org\/10.1038\/s41568-021-00346-0.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"7_CR158","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41541-022-00503-y","volume":"7","author":"T Travieso","year":"2022","unstructured":"Travieso T, Li J, Mahesh S, Mello J, Blasi M. The use of viral vectors in vaccine development. NPJ Vaccines. 2022;7(1):75. https:\/\/doi.org\/10.1038\/s41541-022-00503-y.","journal-title":"NPJ Vaccines"},{"key":"7_CR159","doi-asserted-by":"publisher","unstructured":"Sharma B, Bekerman E, Truong H, Lee J, Gamez-Guerrero M, Boopathy A, et al. Arenavirus-based vectors generate robust SIV immunity in non-human primates. Vaccines (Basel). 2024;12(7) https:\/\/doi.org\/10.3390\/vaccines12070735.","DOI":"10.3390\/vaccines12070735"},{"issue":"1","key":"7_CR160","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40425-018-0495-7","volume":"7","author":"ZS Guo","year":"2019","unstructured":"Guo ZS, Lu B, Guo Z, Giehl E, Feist M, Dai E, et al. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. J Immunother Cancer. 2019;7(1):6. https:\/\/doi.org\/10.1186\/s40425-018-0495-7.","journal-title":"J Immunother Cancer"},{"key":"7_CR161","doi-asserted-by":"publisher","unstructured":"Beyaert S, Machiels JP, Schmitz S. Vaccine-based immunotherapy for head and neck cancers. Cancers (Basel). 2021;13(23) https:\/\/doi.org\/10.3390\/cancers13236041.","DOI":"10.3390\/cancers13236041"},{"issue":"1","key":"7_CR162","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10238-024-01436-7","volume":"24","author":"DW Wu","year":"2024","unstructured":"Wu DW, Jia SP, Xing SJ, Ma HL, Wang X, Tang QY, et al. Personalized neoantigen cancer vaccines: current progression, challenges and a bright future. Clin Exp Med. 2024;24(1):229. https:\/\/doi.org\/10.1007\/s10238-024-01436-7.","journal-title":"Clin Exp Med"},{"key":"7_CR163","doi-asserted-by":"publisher","unstructured":"Sun D, Shi X, Li S, Wang X, Yang X, Wan M. CAR-T cell therapy: a breakthrough in traditional cancer treatment strategies (Review). Mol Med Rep. 2024;29(3) https:\/\/doi.org\/10.3892\/mmr.2024.13171.","DOI":"10.3892\/mmr.2024.13171"},{"issue":"8000","key":"7_CR164","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","volume":"626","author":"E Vivier","year":"2024","unstructured":"Vivier E, Rebuffet L, Narni-Mancinelli E, Cornen S, Igarashi RY, Fantin VR. Natural killer cell therapies. Nature. 2024;626(8000):727\u201336. https:\/\/doi.org\/10.1038\/s41586-023-06945-1.","journal-title":"Nature"},{"issue":"4","key":"7_CR165","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707\u201323. https:\/\/doi.org\/10.1016\/j.cell.2017.01.017.","journal-title":"Cell"},{"key":"7_CR166","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.coi.2018.03.008","volume":"51","author":"S Chaurasiya","year":"2018","unstructured":"Chaurasiya S, Chen NG, Fong Y. Oncolytic viruses and immunity. Curr Opin Immunol. 2018;51:83\u201390. https:\/\/doi.org\/10.1016\/j.coi.2018.03.008.","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"7_CR167","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","volume":"8","author":"D Lin","year":"2023","unstructured":"Lin D, Shen Y, Liang T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther. 2023;8(1):156. https:\/\/doi.org\/10.1038\/s41392-023-01407-6.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"7_CR168","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1093\/infdis\/jiy565","volume":"219","author":"JH Poetsch","year":"2019","unstructured":"Poetsch JH, Dahlke C, Zinser ME, Kasonta R, Lunemann S, Rechtien A, et al. Detectable vesicular stomatitis virus (VSV)-specific humoral and cellular immune responses following VSV-Ebola virus vaccination in humans. J Infect Dis. 2019;219(4):556\u201361. https:\/\/doi.org\/10.1093\/infdis\/jiy565.","journal-title":"J Infect Dis"},{"key":"7_CR169","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.898631","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Nagalo BM. Immunovirotherapy based on recombinant vesicular stomatitis virus: where are we? Front Immunol. 2022;13:898631. https:\/\/doi.org\/10.3389\/fimmu.2022.898631.","journal-title":"Front Immunol"},{"key":"7_CR170","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.837835","volume":"12","author":"AWY Chai","year":"2022","unstructured":"Chai AWY, Yee PS, Cheong SC. Rational combinations of targeted therapy and immune checkpoint inhibitors in head and neck cancers. Front Oncol. 2022;12:837835. https:\/\/doi.org\/10.3389\/fonc.2022.837835.","journal-title":"Front Oncol"},{"issue":"6","key":"7_CR171","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S1470-2045(21)00136-4","volume":"22","author":"AG Sacco","year":"2021","unstructured":"Sacco AG, Chen R, Worden FP, Wong DJL, Adkins D, Swiecicki P, et al. Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. Lancet Oncol. 2021;22(6):883\u201392. https:\/\/doi.org\/10.1016\/S1470-2045(21)00136-4.","journal-title":"Lancet Oncol"},{"key":"7_CR172","doi-asserted-by":"publisher","unstructured":"Chung CH, Bonomi M, Steuer CE, Li J, Bhateja P, Johnson M, et al. Concurrent cetuximab and nivolumab as a second-line or beyond treatment of patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: results of phase I\/II study. Cancers (Basel). 2021;13(5) https:\/\/doi.org\/10.3390\/cancers13051180.","DOI":"10.3390\/cancers13051180"},{"issue":"2","key":"7_CR173","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212513","volume":"14","author":"Y Kato","year":"2019","unstructured":"Kato Y, Tabata K, Kimura T, Yachie-Kinoshita A, Ozawa Y, Yamada K, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 2019;14(2):e0212513. https:\/\/doi.org\/10.1371\/journal.pone.0212513.","journal-title":"PLoS One"},{"issue":"10","key":"7_CR174","doi-asserted-by":"publisher","first-page":"e003476","DOI":"10.1136\/jitc-2021-003476","volume":"9","author":"M Oliva","year":"2021","unstructured":"Oliva M, Chepeha D, Araujo DV, Diaz-Mejia JJ, Olson P, Prawira A, et al. Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study. J Immunother Cancer. 2021;9(10):e003476. https:\/\/doi.org\/10.1136\/jitc-2021-003476.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"7_CR175","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1261779","volume":"6","author":"G Shayan","year":"2017","unstructured":"Shayan G, Srivastava R, Li J, Schmitt N, Kane LP, Ferris RL. Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer. Onco Targets Ther. 2017;6(1):e1261779. https:\/\/doi.org\/10.1080\/2162402X.2016.1261779.","journal-title":"Onco Targets Ther"},{"issue":"23","key":"7_CR176","doi-asserted-by":"publisher","first-page":"6335","DOI":"10.1158\/1078-0432.CCR-20-1066","volume":"26","author":"TA Proia","year":"2020","unstructured":"Proia TA, Singh M, Woessner R, Carnevalli L, Bommakanti G, Magiera L, et al. STAT3 antisense oligonucleotide remodels the suppressive tumor microenvironment to enhance immune activation in combination with anti-PD-L1. Clin Cancer Res. 2020;26(23):6335\u201349. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1066.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"7_CR177","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1910231.","journal-title":"N Engl J Med"},{"issue":"14","key":"7_CR178","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1709684.","journal-title":"N Engl J Med"},{"issue":"2","key":"7_CR179","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1001\/jamaoncol.2018.4628","volume":"5","author":"LL Siu","year":"2019","unstructured":"Siu LL, Even C, Mesia R, Remenar E, Daste A, Delord JP, et al. Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low\/negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial. JAMA Oncol. 2019;5(2):195\u2013203. https:\/\/doi.org\/10.1001\/jamaoncol.2018.4628.","journal-title":"JAMA Oncol"},{"key":"7_CR180","doi-asserted-by":"publisher","unstructured":"Li H, Zandberg DP, Kulkarni A, Chiosea SI, Santos PM, Isett BR, et al. Distinct CD8(+) T cell dynamics associate with response to neoadjuvant cancer immunotherapies. Cancer Cell. 2025; https:\/\/doi.org\/10.1016\/j.ccell.2025.02.026.","DOI":"10.1016\/j.ccell.2025.02.026"},{"issue":"11","key":"7_CR181","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1158\/0008-5472.CAN-14-3511","volume":"75","author":"C Vanpouille-Box","year":"2015","unstructured":"Vanpouille-Box C, Diamond JM, Pilones KA, Zavadil J, Babb JS, Formenti SC, et al. TGFbeta is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res. 2015;75(11):2232\u201342. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-3511.","journal-title":"Cancer Res"},{"issue":"6","key":"7_CR182","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","volume":"14","author":"RR Weichselbaum","year":"2017","unstructured":"Weichselbaum RR, Liang H, Deng L, Fu YX. Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol. 2017;14(6):365\u201379. https:\/\/doi.org\/10.1038\/nrclinonc.2016.211.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"7_CR183","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1356153","volume":"6","author":"A Oweida","year":"2017","unstructured":"Oweida A, Lennon S, Calame D, Korpela S, Bhatia S, Sharma J, et al. Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma. Onco Targets Ther. 2017;6(10):e1356153. https:\/\/doi.org\/10.1080\/2162402X.2017.1356153.","journal-title":"Onco Targets Ther"},{"issue":"12","key":"7_CR184","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/S1470-2045(24)00507-2","volume":"25","author":"LK Mell","year":"2024","unstructured":"Mell LK, Torres-Saavedra PA, Wong SJ, Kish JA, Chang SS, Jordan RC, et al. Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2\/3 trial. Lancet Oncol. 2024;25(12):1576\u201388. https:\/\/doi.org\/10.1016\/S1470-2045(24)00507-2.","journal-title":"Lancet Oncol"},{"issue":"14","key":"7_CR185","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1200\/JCO.2016.70.1524","volume":"35","author":"J Bauml","year":"2017","unstructured":"Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J Clin Oncol. 2017;35(14):1542\u20139. https:\/\/doi.org\/10.1200\/JCO.2016.70.1524.","journal-title":"J Clin Oncol"},{"issue":"4","key":"7_CR186","doi-asserted-by":"publisher","first-page":"e98811","DOI":"10.1172\/jci.insight.98811","volume":"3","author":"GJ Hanna","year":"2018","unstructured":"Hanna GJ, Lizotte P, Cavanaugh M, Kuo FC, Shivdasani P, Frieden A, et al. Frameshift events predict anti-PD-1\/L1 response in head and neck cancer. JCI Insight. 2018;3(4):e98811. https:\/\/doi.org\/10.1172\/jci.insight.98811.","journal-title":"JCI Insight"},{"issue":"6","key":"7_CR187","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Sautes-Fridman","year":"2019","unstructured":"Sautes-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19(6):307\u201325. https:\/\/doi.org\/10.1038\/s41568-019-0144-6.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"7_CR188","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/annonc\/mdy470","volume":"30","author":"YP Chen","year":"2019","unstructured":"Chen YP, Wang YQ, Lv JW, Li YQ, Chua MLK, Le QT, et al. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy. Ann Oncol. 2019;30(1):68\u201375. https:\/\/doi.org\/10.1093\/annonc\/mdy470.","journal-title":"Ann Oncol"}],"container-title":["Cancer Treatment and Research","Immunotherapies in Solid Tumors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-97242-3_7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:04:25Z","timestamp":1778886265000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-97242-3_7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031972416","9783031972423"],"references-count":188,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-97242-3_7","relation":{},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"value":"0927-3042","type":"print"},{"value":"2509-8497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"23 August 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}